Quarterly Report • Apr 24, 2025
Quarterly Report
Open in ViewerOpens in native device viewer
| Key figures | Jan-Mar | Full year | RTM | ||
|---|---|---|---|---|---|
| 2025 | 2024 | 2024 | 2024/25 | ||
| Total revenue¹,MSEK | 62.7 | 58.8 | 261.9 | 265.8 | |
| Operating profit/loss¹,MSEK | -2.6 | -12.9 | -28.9 | -18.6 | |
| EBITDA²,MSEK | 9.4 | -1.5 | 18.0 | 28.9 | |
| EBITDA margin²,% | 15.0 | -2.6 | 6.9 | 10.9 | |
| Net profit/loss for the period¹,MSEK | -4.7 | -9.9 | -29.8 | -24.6 | |
| Earnings per share¹,SEK | -0.13 | -0.28 | -0.85 | -0.70 | |
| Cash flow from operating activities ¹,MSEK | -12.1 | -19.1 | 25.0 | 31.9 | |
| Cash flow from operating activities, per share²,SEK | -0.35 | -0.54 | 0.71 | 0.91 | |
| Equity ratio²,% | 55.2 | 51.3 | 50.1 | 55.2 | |
| Net debt²,MSEK | 124.4 | 145.7 | 111.0 | 124.4 |
1 Defined according to IFRS.
2 Alternative performance measure. For definition and reconciliation, see pages 14-15.
Following the 2024 financial turnaround, we continue our profitable path with yet another strong quarter. EBITDA amounted to SEK 9.4 million (Q1 2024: SEK -1.5 million) and revenues increased by 6.7 percent compared to Q1 last year and landed at SEK 62.7 million (Q1 2024: SEK 58.8 million). Our license business developed well, primarily driven by the successful collaboration with license partner BD, demonstrating a consistent positive financial performance thanks to our strategic transition. The Wound Management portfolio also had a strong quarter with a revenue increase of more than 50 percent, fueled by a significant rise in sales of Hydrocyn aqua. During the quarter, we also updated our strategic and financial targets and core therapeutic areas, areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device related infections.
Total license revenues for Q1 amounted to SEK 39.3 million (Q1 2024: SEK 35.1 million). Revenues from license partner MedTech company BD (Becton, Dickinson & Company) were SEK 32.2 million for Q1 (Q1 2024: SEK 28.0 million). Our successful and expanding collaboration – spanning the entire value chain from technology license to go-to-market strategies – remains the cornerstone in our partnership. A recent example from March this year was when Bactiguard and BD were at leading healthcare conference in India, CRITICARE 2025. This marked an important step in informing local stakeholders and key opinion leaders that BD will take over the sales and distribution of Bactiguard-coated Foley catheters in India. Revenues from Zimmer Biomet for Q1 amounted to SEK 0.9 million (Q1 2024: SEK 3.2 million) and consist of royalties related to the trauma agreement. Commercialization of the ZNN Bactiguard orthopedic trauma nail continued, particularly in Europe. Our activities on the MDR transition across Europe also continued during the quarter. In parallel, Zimmer Biomet has four clinical trials ongoing, focusing on infection rates, safety, and clinical outcomes.
The Wound Management portfolio had a strong first quarter with revenues of SEK 19.2 million (Q1 2024: SEK 12.7 million). The increase was driven by a significant rise in sales of Wound Management's main brand Hydrocyn aqua. During the quarter, our Malaysia facilities were ISO 14001 certified from the British Standards Institution manifesting our commitment to high quality and responsible manufacturing and production processes.
In March, we announced our refined strategic therapeutic areas concentrating on where Bactiguard's technology offers the greatest and most realizable potential, in essence areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device related infections. This was also reflected in our updated targets: delivering at least SEK 600 million in revenue and at least SEK 200 million in EBITDA by year-end 2030 supported by a goal of securing at least ten application areas in exclusivity or license partnership. Our scalable business model, combined with strong operational leverage, is expected to deliver significant value beyond 2030 through partnerships established in the years ahead.
With our existing business as the primary driver of our 2030 targets, our strengthened R&D and regulatory capabilities are empowering new business development. A key priority is deepening existing licensing partnerships, such as with BD, while leveraging our innovation in infection prevention to forge new strategic partnership collaborations.
Global market conditions are more volatile and unpredictable than ever. Still, we believe that companies with a clear long-term strategy and strong fundamentals are better positioned to navigate these turbulent times. While it is impossible to predict the duration of the current uncertainties, our current assessment indicates that the US tariffs have no direct impact on Bactiguard. However, Bactiguard has substantial USD exposure in the license business and a weaker USD will have a negative effect on our results. Notably, we do not hedge our currency exposure. We continue to monitor developments closely, given the rapidly evolving landscape.
More importantly, by delivering yet another profitable quarter, Bactiguard has established a solid foundation to achieve the updated strategic and financial targets, while maintaining a clear focus on growth and profitability.
Christine Lind, CEO
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices.
Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies that apply the infection prevention technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. Our license-focused business model is scalable with operational leverage.
Bactiguard's license revenues have three components: we receive revenues for coating and process development, we receive revenues for the right to use the coating technology on medical devices within a specific application and geographical area, and we receive royalties – a variable remuneration once the license partners' products reach the market. The revenues are generated across three partnership phases: application development, exclusivity and license.
An application development partner works in close collaboration with Bactiguard's R&D team exploring the application of our infection prevention technology to the partners' underlying device to enhance its performance. The nature of development work means that not every project will succeed, but the learnings are valuable for other application areas.
An exclusivity partner gets exclusive rights to apply our coating technology to a certain medical device but has no products in the market yet, for instance due to pending regulatory approvals, which can take time depending on the type of application and its classification.
A license partner has the right to market and sell medical devices with Bactiguard's coating technology, in a certain region or globally.
Not all partnerships will follow all three phases. An agreement with a partner can generate revenues from separate phases and components simultaneously.
| Partnerships | Application area | Market |
|---|---|---|
| Becton, Dickinson & Company (BD) | Urinary catheters (Foley) | Global excl. China |
| Zimmer Biomet | Trauma implants | Global excl. Southeast Asia, China, India, and South Korea |
| Well Lead Medical | Urinary catheters | China |
| Jan-Mar | RTM | ||||
|---|---|---|---|---|---|
| MSEK | 2025 | 2024 | 2024 | 2024/25 | |
| Total license revenue | 39.3 | 35.1 | 164.7 | 168.8 | |
| License partners | 39.3 | 32.4 | 155.4 | 162.2 | |
| Exclusivity partners | - | 2.6 | 7.7 | 5.2 | |
| Application development partners | 0.0 | 0.1 | 1.5 | 1.5 | |
| Wound Management portfolio | 19.2 | 12.7 | 60.9 | 67.3 | |
| BIP portfolio | 0.5 | 6.0 | 16.0 | 10.7 | |
| Net sales | 59.1 | 53.9 | 241.7 | 246.8 | |
| Other operating revenues | 3.7 | 4.9 | 20.2 | 19.0 | |
| Total revenue | 62.7 | 58.8 | 261.9 | 265.8 |
Total revenue for the first quarter amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million, corresponding to 6.7 percent. Adjusted for currency effects of SEK 2.9 million, revenue increased by 1.7 percent.
Net sales amounted to SEK 59.1 (53.9) million, an increase of SEK 5.1 million, corresponding to 9.5 percent. Adjusted for currency effects of SEK 1.7 million, net sales increased by 6.3 percent.
Total license revenue amounted to SEK 39.3 (35.1) million, an increase of SEK 4.2 million, corresponding to 11.8 percent. Adjusted for currency effects of SEK 1.8 million, license revenues increased by 6.7 percent. Revenues from Becton, Dickinson & Company (BD) amounted to SEK 32.2 (28.0) million, an increase of SEK 4.2 million, corresponding to 15.1 percent. Adjusted for currency effects of SEK 1.8 million, revenues from BD increased by 8.5 percent. Revenues from Zimmer Biomet amounted to SEK 0.9 (3.2) million, a decrease of SEK 2.3 million, corresponding to 73.3 percent with and without currency effects. These revenues pertain mainly to royalties from the Trauma product segment agreement.
Revenues from license partners amounted to SEK 39.3 (32.4) million, an increase of SEK 6.8 million, corresponding to 21.1 percent. Adjusted for currency effects of SEK 1.8 million, revenues from license partners increased by 15.6 percent.
Revenues from exclusivity partners amounted to SEK 0.0 (2.6) million, a decrease of SEK 2.6 million.
Revenues from application development partners amounted to SEK 0.0 (0.1) million, a decrease of SEK 0.1 million.
Revenues from Wound Management portfolio amounted to SEK 19.2 (12.7) million, an increase of SEK 6.5 million, corresponding to 50.8 percent with and without currency effects.
Revenues from the BIP portfolio amounted to SEK 0.5 (6.0) million, a decrease of SEK 5.5 million, corresponding to 90.9 percent with and without currency effects. As planned, we do not expect any significant BIP revenues in 2025.
Other revenues amounted to SEK 3.7 (4.9) million, a decrease of SEK 1.2 million, corresponding to 24.2 percent. Currency effects amounted to SEK 1.2 (2.8) million and the remaining revenue primarily relates to rent income.
Costs for raw materials and consumables for the first quarter amounted to SEK -12.2 (-11.5) million, an increase of SEK 0.8 million, corresponding to 6.7 percent. Other external costs amounted to SEK -15.6 (-18.8) million, a decrease of SEK 3.1 million, corresponding to 16.7 percent. Personnel costs amounted to SEK -23.1 (-29.4) million, a decrease of SEK 6.2 million, corresponding to 21.3 percent. Other operating expenses are related to currency exchange losses/gains, which amounted to SEK -3.6 (-0.7) million. Total operating expenses (OPEX) amounted to SEK -42.4 (-48.8) million, a decrease of SEK 6.5 million, corresponding to 13.3 percent.
The operating loss amounted to SEK 2.6 (12.9) million, a decrease of SEK 10.3 million, corresponding to 79.7 percent. The improved operating result mainly pertained to the increase in total license revenues while keeping costs under control.
EBITDA for the first quarter amounted to SEK 9.4 (-1.5) million, an increase of SEK 10.9 million. The EBITDA margin was 15.0 (-2.6) percent.
Depreciation and amortization amounted to SEK -12.0 (-11.4) million, an increase of SEK 0.7 million, corresponding to 5.8 percent. Amortization of intangible assets amounted to SEK -7.1 (-6.8) million, attributable primarily to amortization of SEK -6.4 (-6.4) million related to Bactiguard's technology. Depreciation of tangible assets amounted to SEK -4.9 (-4.5) million, primarily attributable to depreciation on leasing of SEK -3.4 (-3.6) million.
Financial items amounted to SEK -4.9 (0.7) million. Financial income amounted to SEK 0.0 (4.5) million. Financial expenses amounted to SEK -4.9 (-3.9) million which mainly pertained to interest expenses of SEK -2.6 (-3.6) million.
Tax for the period amounted to SEK 0.0 (0.0) million. Change in deferred tax amounted to SEK 2.8 (2.3) million attributable to the intangible assets and leases, which is calculated at the Swedish tax rate of 20.6 percent. Income tax in foreign subsidiaries is calculated on the basis of a tax rate of 24.0 percent.
Net loss for the first quarter of 2025 amounted to SEK 4.7 (9.9) million.
Cash flow from operating activities for the quarter amounted to SEK -12.1 (-19.1) million. Change in working capital for the quarter amounted to SEK -8.8 (-11.3) million.
Cash flow from investing activities for the quarter amounted to SEK -0.1 (-6.2) million.
Cash flow from financing activities for the quarter amounted to SEK -55.5 (-6.3) million, mainly pertained to the amortization of SEK 51.0 million of the financing with SEB.
Cash flow for the quarter amounted to SEK -67.7 (-31.6) million. Cash and cash equivalents at the end of the period of 31 March 2025 amounted to SEK 46.8 (95.8) million.
Equity on 31 March 2025 amounted to SEK 318 (343) million and net debt to SEK 124 (146) million. Total assets on 31 March 2025 amounted to SEK 576 (669) million.
As of 31 March 2025, the parent company's liabilities with SEB amounted to SEK 120.0 (170.9) million. As of 31 March 2025, the approved overdraft facility from SEB of SEK 30 million was not utilized. Foreign subsidiaries had credit facilities amounting to SEK 8.0 (3.3) million, of which SEK 1.0 million was utilized as of 31 March 2025.
At the beginning of February 2025, the company amortized SEK 51.0 million of the SEK 170.9 million financing with SEB, while securing SEK 120.0 million in new financing on better terms. The new loan runs for two years and with an option to extend it for another year.
Full-time equivalents in the Group during the period January to March averaged to 146 (196) FTE of which 101 (119) are women. On 31 March 2025, the number of full-time equivalents was 147 FTE.
Bactiguard's B share is listed on Nasdaq Stockholm with the short name "BACTI B". The closing price for the B share was SEK 29.8 (72.4) on 31 March 2025 and the market capitalization amounted to SEK 1,044 (2,537) million.
The share capital in Bactiguard on 31 March 2025 amounted to SEK 0.9 (0.9) million divided into 31,043,885 Class B shares with one vote each (31,043,885 votes) and 4,000,000 Class A shares with ten votes each (40,000,000 votes). The total number of shares and votes in Bactiguard on 31 March 2025 was 35,043,885 shares and 71,043,885 votes.
| Shareholders | No. of A shares |
No. of B | shares Total number | % of capital | % of votes |
|---|---|---|---|---|---|
| TomBact AB¹ | 2,000,000 | 4,443,787 | 6,443,787 | 18.4 | 34.4 |
| GIDL Invest AB² | 2,000,000 | 4,106,497 | 6,106,497 | 17.4 | 33.9 |
| Nordea Funds | 3,648,811 | 3,648,811 | 10.4 | 5.1 | |
| Jan Ståhlberg | 3,605,150 | 3,605,150 | 10.3 | 5.1 | |
| The Fourth Swedish National Pension Fund | 3,475,992 | 3,475,992 | 9.9 | 4.9 | |
| Handelsbanken Fonder | 2,070,099 | 2,070,099 | 5.9 | 2.9 | |
| TomEnterprise Public Capital AB¹ | 1,885,384 | 1,885,384 | 5.4 | 2.7 | |
| AMF - försäkring och fonder | 1,712,088 | 1,712,088 | 4.9 | 2.4 | |
| Insurance company Avanza Pension | 1,084,768 | 1,084,768 | 3.1 | 1.5 | |
| Lancelot Asset Management AB | 500,000 | 500,000 | 1.4 | 0.7 | |
| Total, major shareholders | 4,000,000 | 26,532,576 | 30,532,576 | 87.1 | 93.6 |
| Total, others | 4,511,309 | 4,511,309 | 12.9 | 6.4 | |
| Total number of shares | 4,000,000 | 31,043,885 | 35,043,885 | 100.0 | 100.0 |
1 Company controlled by Thomas von Koch.
2 Company controlled by Christian Kinch.
Per 31 March 2025 Bactiguard had 2,921 (3,260) shareholders.
At the beginning of February 2025, the company amortized SEK 51.0 million of the SEK 170.9 million financing with SEB, while securing SEK 120.0 million in new financing on better terms. The new loan runs for two years and with an option to extend it for another year.
New financial targets, to be delivered by year-end 2030, were published: Revenues SEK 600 million, EBITDA SEK 200 million and 10 application areas in either exclusivity partnerships or license partnerships.
On 2 April 2025, the United States government announced a new tariff regime introducing a 10 percent baseline tariff on all imported goods, with higher rates (up to 46 percent) applied to selected countries, including EU countries. These tariffs are scheduled to take effect in phases beginning 5 April 2025. This policy change may directly or indirectly impact the cost and flow of goods, potentially affecting pricing, margins, and future demand. Bactiguard is actively monitoring the situation and assessing potential levers to mitigate any adverse effects.
Following a review announced in connection with the 2024 Q3 report, Bactiguard updated its strategic and financial targets on 5 March 2025. The company has since then conducted a comprehensive analysis of the market potential and partnership opportunities for its infection prevention technology. This included an in-depth evaluation of key strategic therapeutic areas, targeted application areas, associated infection rates, regulatory approval timelines, partnership timelines and commercial scale-up potential.
The updated targets reflect a sharpened strategic focus on the license business and EBITDA profitability, a transformation which was delivered in 2024.
Revenues: deliver revenues of at least SEK 600 million by year-end 2030
EBITDA: deliver an EBITDA of at least SEK 200 million by year-end 2030
Partnership development: have at least ten application areas in either exclusivity partnerships or license partnerships by year-end 2030
These targets replace the 2028 goals set in October 2023. Bactiguard remains committed to EBITDA profitability, disciplined cost management, and growth in both license partnerships and wound management, with the latter continuing its double-digit profitability.
These targets represent mid-term expectations rather than forecasts, as Bactiguard sharpens its focus on Orthopedics, Cardiology, Neurology, Urology and Vascular Access while investing in R&D and business development for long-term growth.
The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS). The interim report has been prepared in accordance with IAS 34 Interim Reporting and the Annual Accounts Act. Disclosures in accordance with IAS 34 Interim Reporting are submitted both in notes and elsewhere in the interim report. The parent company's financial statements have been prepared in accordance with the Annual Accounts Act and the Financial Reporting Board's recommendation, RFR 2 Accounting for Legal Entities.
Accounting and valuation principles are stated in the annual report 2024. The accounting principles are unchanged from previous periods.
An operating segment is a component of an entity that engages in business activities from which it may derive revenues and incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which there is separate financial information. The company's reporting of operating segments is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function that assesses the operating segment performance and decides how to allocate resources. The company has determined that the Group's executive management constitutes of the chief operating decision maker. The company is considered in its entirety to operate within one business segment.
During the period, the parent company has received compensation for services and interest on its receivables from group companies. No investments were made during the period.
Companies within the Group are exposed to various types of risk through their activities. Bactiguard continually engages in a process of identifying all risks that may arise and assessing how each of these risks shall be managed. The Group is working to create an overall risk management program that focuses on minimizing potential adverse effects on the company's financial results. The company is primarily exposed to financial risks, market risks and operational risks. A description of these risks can be found on page 18-19 and 53–55 in the annual report 2024.
In addition to identified risks, the macro situation and its impact is continuously monitored. The global healthcare challenges have a significant impact on society. The need for more efficient and safe healthcare is driven by both economic and demographic developments, as well as increased political unrest, conflicts, wars, and natural disasters. Particularly prominent are healthcare-associated infections and antimicrobial resistance where we see an increased interest in infection prevention.
Bactiguard does not have suppliers in or sales to any of Russia, Belarus, or Ukraine. However, the global economy is affected by the situation of the war, and we follow developments closely and continuously evaluate the operational and financial effects as the global situation may change and affect the company's financial position. Bactiguard has a subsidiary in Israel. We are closely following the developments there and our primary focus is to ensure the staff's well-being and security. We make the assessment that the conflict in Israel will have a negligible effect on the group's result and financial position.
While we see falling inflation levels, inflation and higher prices can continue to affect the company negatively as it is not always possible to change the price to the customers, all of which can affect the financial position negatively. The falling inflation levels can lead to lower interest rates, which can positively impact the interest costs. Some countries are now in or close to recession, which can lead to a decreased ability for customers to pay their invoices. Bactiguard has substantial USD exposure in the license business and a weaker USD will have a negative effect on the results, see page 55 in the annual report 2024. The company does not hedge the currency exposure. Developments are monitored closely, given the rapidly evolving landscape.
| Jan-Mar | Full year | RTM | |||
|---|---|---|---|---|---|
| TSEK | Note | 2025 | 2024 | 2024 | 2024/25 |
| Revenues | 1 | ||||
| Net sales | 59,053 | 53,926 | 241,678 | 246,805 | |
| Other operating income | 3,687 | 4,867 | 20,200 | 19,019 | |
| Total | 62,740 | 58,793 | 261,877 | 265,824 | |
| Change in inventory of finished goods and products in progress | 1,273 | 28 | 148 | 1,393 | |
| Capitalized production | - | - | - | - | |
| Raw materials and consumables | -12,242 | -11,475 | -36,117 | -36,884 | |
| Other external expenses | -15,615 | -18,751 | -87,567 | -84,431 | |
| Personnel costs | -23,128 | -29,375 | -111,462 | -105,215 | |
| Depreciation and amortization | -12,020 | -11,366 | -46,883 | -47,537 | |
| Other operating expenses | -3,619 | -721 | -8,857 | -11,756 | |
| Total | -65,351 | -71,660 | -290,738 | -284,429 | |
| Operating profit/loss | -2,612 | -12,867 | -28,860 | -18,607 | |
| Profit/loss from financial items | |||||
| Financial income | 16 | 4,536 | 7,844 | 3,323 | |
| Financial expenses | -4,883 | -3,869 | -15,566 | -16,580 | |
| Total | -4,867 | 667 | -7,722 | -13,257 | |
| Profit/loss before tax | -7,478 | -12,200 | -36,585 | -31,863 | |
| Current tax | - | - | - | - | |
| Deferred tax | 2,750 | 2,299 | 6,769 | 7,220 | |
| NET PROFIT/LOSS FOR THE PERIOD | -4,728 | -9,901 | -29,815 | -24,643 | |
| Attributable to: | |||||
| The parent company´s shareholders | -4,728 | -9,901 | -29,815 | -24,643 | |
| Earnings per share, before and after dilution, SEK | -0.13 | -0.28 | -0.85 | -0.70 |
| Jan-Mar | Full year | RTM | |||
|---|---|---|---|---|---|
| TSEK | Note | 2025 | 2024 | 2024 | 2024/25 |
| Net profit/loss for the period | -4,728 | -9,901 | -29,815 | -24,640 | |
| Other comprehensive income: | |||||
| Items that will not be reclassified to profit or loss for the year | - | - | - | - | |
| Items that will be reclassified to profit or loss for the year | |||||
| Translation differences | -5,933 | 127 | 4,979 | -1,081 | |
| Other comprehensive income, after tax | -5,933 | 127 | 4,979 | -1,081 | |
| TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | -10,661 | -9,774 | -24,836 | -25,721 | |
| Attributable to: | |||||
| The parent company´s shareholders | -10,661 | -9,774 | -24,836 | -25,721 | |
| Number of shares at the end of period ('000) | 35,044 | 35,044 | 35,044 | 35,044 | |
| Weighted average number of shares ('000) | 35,044 | 35,044 | 35,044 | 35,044 |
| TSEK | Note 2025-03-31 | 2024-03-31 | 2024-12-31 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Intangible fixed assets | |||
| Goodwill | 248,680 | 249,091 | 251,817 |
| Technology | 41,814 | 66,903 | 48,179 |
| Brands | 25,579 | 25,691 | 25,602 |
| Customer relationships | 3,496 | 4,740 | 3,856 |
| Capitalized development costs | 1,344 | 2,953 | 1,619 |
| Patent | 870 | 1,244 | 962 |
| Total | 321,783 | 350,622 | 332,035 |
| Tangible assets | |||
| Right of use lease assets | 48,498 | 62,567 | 52,685 |
| Buildings | 22,973 | 23,739 | 25,588 |
| Leasehold improvements | 18,004 | 8,913 | 18,513 |
| Machinery and other technical plant | 5,578 | 6,886 | 6,554 |
| Equipment, tools and installations | 5,838 | 10,200 | 5,837 |
| Total | 100,890 | 112,305 | 109,177 |
| Financial assets | |||
| Other non-current receivables | 2,889 | 3,053 | 2,937 |
| Total | 2,889 | 3,053 | 2,937 |
| Deferred tax assets | 20,296 | 11,735 | 17,517 |
| Total non-current assets | 445,858 | 477,715 | 461,669 |
| Current assets | |||
| Inventory | 21,400 | 29,337 | 26,231 |
| Accounts receivable | 35,079 | 33,647 | 25,046 |
| Other current receivables 2 |
13,578 | 10,382 | 12,960 |
| Prepaid expenses and accrued income Cash and cash equivalents |
12,846 | 22,508 95,839 |
13,279 116,727 |
| Total current assets | 46,814 129,717 |
191,713 | 194,243 |
| TOTAL ASSETS | 575,575 | 669,428 | 655,911 |
| EQUITY AND LIABILITIES | |||
| Equity attributable to shareholders of the parent | |||
| Share capital | 876 | 876 | 876 |
| Translation reserve | 4,124 | -728 | 4,124 |
| Other capital contribution | 930,680 | 930,680 | 930,680 |
| Retained earnings including net profit/loss for the period | -617,999 | -587,424 | -607,338 |
| Total equity | 317,681 | 343,404 | 328,342 |
| Non-current liabilities | |||
| Liabilities to credit institutions | 118,845 | 170,940 | - |
| Leasing liabilities | 38,232 | 50,668 | 40,694 |
| Provisions | 5,257 | 5,257 | 5,257 |
| Other long-term liabilities | - | 125 | - |
| Total non-current liabilities | 162,334 | 226,990 | 45,951 |
| Current liabilities | |||
| Liabilities to credit institutions | - | 3,870 | 170,893 |
| Leasing liabilities | 14,152 | 16,051 | 16,180 |
| Accounts payable | 23,723 | 19,757 | 22,925 |
| Provisions | 17,175 | 9,568 | 18,104 |
| Other current liabilities 2 |
2,369 | 3,004 | 3,312 |
| Accrued expenses and prepaid income | 38,140 | 46,784 | 50,204 |
| Total current liabilities | 95,559 | 99,034 | 281,618 |
| TOTAL LIABILITIES | 257,893 | 326,024 | 327,569 |
| TOTAL EQUITY AND LIABILITIES | 575,575 | 669,428 | 655,911 |
| Retained | |||||
|---|---|---|---|---|---|
| earnings | |||||
| Other | including net | ||||
| Share | capital | profit/loss for | |||
| TSEK | capital | contribution | Reserves | the period | Total equity |
| Opening balance 2024-01-01 | 876 | 930,680 | -855 | -577,523 | 353,178 |
| Net profit/loss for the period | - | - | - | -9,901 | -9,901 |
| Other comprehensive income: | |||||
| Translation differences | - | - | 127 | - | 127 |
| Total comprehensive income after tax | - | - | 127 | -9,901 | -9,774 |
| Closing balance 2024-03-31 | 876 | 930,680 | -728 | -587,424 | 343,404 |
| Opening balance 2025-01-01 | 876 | 930,680 | 4,124 | -607,338 | 328,342 |
| Net profit/loss for the period | - | - | - | -4,728 | -4,728 |
| Other comprehensive income: | |||||
| Translation differences | - | - | -5,933 | - | -5,933 |
| Total comprehensive income after tax | - | - | -5,933 | -4,728 | -10,661 |
| Closing balance 2025-03-31 | 876 | 930,680 | -1,809 | -612,066 | 317,681 |
| Jan-Mar | Full year | RTM | |||
|---|---|---|---|---|---|
| TSEK | Note | 2025 | 2024 | 2024 | 2024/25 |
| Net profit/loss for the period | -4,728 | -9,901 | -29,815 | -24,643 | |
| Adjustments for depreciation and amortization and other non-cash items |
1,432 | 2,101 | 38,255 | 37,585 | |
| Increase/decrease inventory | 5,583 | 1,178 | 12,858 | 17,263 | |
| Increase/decrease accounts receivable | -10,359 | -15,987 | -7,290 | -1,662 | |
| Increase/decrease other current receivables | -2,916 | -5,044 | -5,031 | -2,903 | |
| Increase/decrease accounts payable | 798 | 3,063 | 6,230 | 3,965 | |
| Increase/decrease other current liabilities | -1,919 | 5,535 | 9,782 | 2,328 | |
| Cash flow from changes in working capital | -8,814 | -11,256 | 16,549 | 18,992 | |
| Cash flow from operating activities | -12,110 | -19,056 | 24,989 | 31,936 | |
| Investments in intangible assets | - | - | - | - | |
| Investments in tangible assets | -128 | -6,225 | -14,781 | -8,684 | |
| Cash flow from investing activities | -128 | -6,225 | -14,781 | -8,684 | |
| Amortization of financial leasing liability | -3,449 | -2,575 | -13,522 | -14,397 | |
| Amortization of loan | -52,048 | -3,759 | -7,676 | -55,965 | |
| Change in bank overdraft | - | - | - | - | |
| Other financing activities | - | - | - | - | |
| Cash flow from financing activities | -55,497 | -6,334 | -21,198 | -70,362 | |
| Cash flow for the period | -67,734 | -31,615 | -10,990 | -47,110 | |
| Cash and cash equivalents at the beginning of the period | 116,727 | 123,217 | 123,217 | 95,839 | |
| Exchange difference in cash and cash equivalents | -2,179 | 4,237 | 4,501 | -1,916 | |
| Cash and cash equivalents at end of period | 46,814 | 95,839 | 116,727 | 46,814 |
| Jan-Mar | RTM | |||
|---|---|---|---|---|
| TSEK Note |
2025 | 2024 | 2024 | 2024/25 |
| Net sales | - | - | 3,423 | 3,423 |
| Total | - | - | 3,423 | 3,423 |
| Other external expenses | -974 | -1,841 | -4,277 | -3,410 |
| Personnel costs | -740 | -783 | -3,096 | -3,053 |
| Total | -1,714 | -2,624 | -7,373 | -6,463 |
| Operating profit/loss | -1,714 | -2,624 | -3,949 | -3,040 |
| Financial income | 3,547 | 5,461 | 20,846 | 18,932 |
| Financial expenses | -2,203 | -3,175 | -12,717 | -11,745 |
| Total | 1,344 | 2,286 | 8,130 | 7,188 |
| Income after financial items | -370 | -338 | 4,180 | 4,148 |
| Deferred tax | - | - | - | - |
| Net profit/loss for the period | -370 | -338 | 4,180 | 4,148 |
The parent company presents no separate statement of comprehensive income since the company has no items in 2025 or 2024 recognized in other comprehensive income. Net profit/loss for the period for the parent company thereby also constitutes of the comprehensive income for the period.
| TSEK | Note 2025-03-31 | 2024-03-31 | 2024-12-31 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Financial assets | |||
| Shares in subsidiaries | 625,191 | 575,191 | 625,191 |
| Receivables from group companies | 297,746 | 363,791 | 351,757 |
| Deferred tax assets | 15,255 | 15,255 | 15,255 |
| Total non-current assets | 938,191 | 954,237 | 992,202 |
| Current assets | |||
| Current receivables | |||
| Other current receivables | 290 | 180 | 1,767 |
| Prepaid expenses and accrued income | 57,701 | 37,963 | 52,887 |
| Total | 57,991 | 38,143 | 54,654 |
| Cash and bank equivalents | 2,897 | 3,388 | 3,562 |
| Total current assets | 60,888 | 41,531 | 58,216 |
| TOTAL ASSETS | 999,079 | 995,768 | 1,050,418 |
| EQUITY & LIABILITIES | |||
| Equity | |||
| Restricted equtiy Share capital |
876 | 876 | 876 |
| Total restricted equity | 876 | 876 | 876 |
| Non-restricted equity | |||
| Non-restricted share premium | 727,969 | 727,969 | 727,969 |
| Retained earnings including net profit/loss for the period | -25,536 | -29,685 | -25,167 |
| Total non-restricted equity | 702,433 | 698,284 | 702,803 |
| Total equity | 703,309 | 699,160 | 703,679 |
| Non-current liabilities | |||
| Liabilities to credit institutions | 120,000 | 170,941 | - |
| Total non-current liabilities | 120,000 | 170,941 | - |
| Current liabilities | |||
| Liabilities to credit institutions | - | - | 170,941 |
| Liabilities to group companies | 174,000 | 124,000 | 174,000 |
| Accounts payable | 239 | 320 | 178 |
| Other current liabilities | 128 | 107 | 320 |
| Accrued expenses and prepaid income | 1,402 | 1,240 | 1,300 |
| Total current liabilities | 175,770 | 125,667 | 346,740 |
| Total liabilities | 295,770 | 296,608 | 346,740 |
| TOTAL EQUITY AND LIABILITIES | 999,079 | 995,768 | 1,050,418 |
Bactiguard presents certain financial measures in its annual report that have not been defined in line with IFRS (referred to as alternative key performance indicators as set forth in the ESMA guidelines). It is the opinion of the company that these measures provide useful supplementary information to investors and the company's management as they allow for the evaluation of the company's performance. Since not all companies calculate the measures in the same way, these are not always comparable to measures used by other companies. These performance measures should therefore not be considered a substitute for measures as defined under IFRS.
The definitions and tables below describe how the performance measures are calculated. The measures are alternative in accordance with ESMA's guidelines unless otherwise stated.
EBITDA presents the company's earning capacity from ongoing operations irrespective of capital structure and tax situation. The key figure is used to facilitate comparisons with other companies in the same industry. The company considers this performance measure to be the most relevant, since the company's technology is depreciated by large amounts, which does not impact cash flow negatively. Bactiguard's patented, unique technology can be applied to a broad range of products in the licensing business.
The company defines EBITDA as operating profit/loss excluding depreciation and amortization of tangible and intangible assets.
| Jan-Mar | Full year | RTM | |||
|---|---|---|---|---|---|
| TSEK | 2025 | 2024 | 2024 | 2024/25 | |
| Operating profit/loss | -2,612 | -12,867 | -28,860 | -18,607 | |
| Depreciation | 12,020 | 11,366 | 46,883 | 47,537 | |
| EBITDA | 9,409 | -1,501 | 18,023 | 28,930 |
Presents the company's earning capacity from ongoing operations, irrespective of capital structure and tax situation, in relation to revenues. The key figure is used to facilitate analysis of the company's result in comparison with comparable companies.
| Jan-Mar | Full year | RTM | ||
|---|---|---|---|---|
| TSEK | 2025 | 2024 | 2024 | 2024/25 |
| EBITDA | 9,409 | -1,501 | 18,023 | 28,930 |
| Revenues | 62,740 | 58,793 | 261,877 | 265,824 |
| EBITDA margin % | 15.0 | -2.6 | 6.9 | 10.9 |
Net debt is a measure used to describe the Group's indebtedness and its ability to repay its debt with cash generated from the Group's operating activities if the debts matured today. The company considers this key figure interesting for creditors who want to understand the Group's debt situation.
The company defines net debt as interest-bearing liabilities minus cash and cash equivalents at the end of the period.
| Jan-Mar | Full year | |||
|---|---|---|---|---|
| TSEK | 2025 | 2024 | 2024 | |
| Non-current liabilities to credit institutions | 118,845 | 170,940 | - | |
| Current liabilities to credit institutions | - | 3,870 | 170,893 | |
| Long-term lease debt | 38,232 | 50,668 | 40,694 | |
| Short-term lease debt | 14,152 | 16,051 | 16,180 | |
| Interest-bearing debt | 171,229 | 241,529 | 227,767 | |
| Cash and cash equivalents | 46,814 | 95,839 | 116,727 | |
| Net debt | 124,415 | 145,690 | 111,040 |
Equity ratio is a measure the company considers important for creditors who want to understand the company's long-term ability to pay. The company defines equity ratio as equity and untaxed reserves (less deferred tax), in relation to the balance sheet total.
| Jan-Mar | Full year | ||
|---|---|---|---|
| TSEK | 2025 | 2024 | 2024 |
| Equity | 317,681 | 343,404 | 328,342 |
| Balance sheet total | 575,575 | 669,428 | 655,911 |
| Equity ratio, % | 55.2 | 51.3 | 50.1 |
Cash flow per share calculated as the cash flow from operating activities divided by the average number of shares outstanding during the period. The key figure is presented because it is used by analysts and other stakeholders to evaluate the company – it shows operating cash flow per share.
Financial income minus financial expenses. Direct reconciliation against financial report is possible.
This performance measure implies the twelve months before and including a certain date.
| Jan-Mar | Full year | RTM | |||
|---|---|---|---|---|---|
| TSEK | 2025 | 2024 | 2024 | 2024/25 | |
| License partners | 39,252 | 32,424 | 155,397 | 162,225 | |
| Exclusivity partners | - | 2,591 | 7,746 | 5,155 | |
| Application development partners | 50 | 131 | 1,548 | 1,467 | |
| Wound Management portfolio | 19,202 | 12,733 | 60,942 | 67,411 | |
| BIP portfolio | 549 | 6,046 | 16,045 | 10,548 | |
| Total | 59,053 | 53,926 | 241,677 | 246,804 | |
| Time for revenue recognition | |||||
| Performance commitment is met at a certain time | 59,003 | 51,203 | 232,384 | 240,184 | |
| Performace commitment is met during a period of time | 50 | 2,722 | 9,294 | 6,622 | |
| Total | 59,053 | 53,926 | 241,677 | 246,804 |
The table below shows the breakdown of financial assets and financial liabilities recognized at fair value in the consolidated balance sheet. Distribution of how fair value is determined is based on three levels.
Level 1: according to prices quoted on an active market for the same instrument.
Level 2: based on directly or indirectly observable market data not included in level 1.
Level 3: based on input data that is not observable on the market.
For description of how fair values have been calculated, see annual report 2024, note 4. Fair value of financial assets and liabilities is estimated to be substantially consistent with posted values. The balance sheet contains receivables and liabilities from the business that are held to maturity. These are reported at amortized cost, which also constitutes an approximation to fair value.
| TSEK | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | RTM 24/25 |
|---|---|---|---|---|---|---|---|
| License partners | 39,252 | 41,205 | 46,639 | 35,129 | 32,424 | 29,544 | 162,225 |
| Exclusivity partners | - | 2,477 | - | 2,678 | 2,591 | 2,639 | 5,155 |
| Application development partners | 50 | 551 | 866 | - | 131 | - | 1,467 |
| Wound Management portfolio | 19,202 | 15,628 | 17,880 | 14,700 | 12,733 | 13,917 | 67,411 |
| BIP portfolio | 549 | 3,213 | 1,939 | 4,847 | 6,046 | 10,152 | 10,548 |
| Other operating revenues | 3,687 | 5,182 | 6,611 | 3,540 | 4,867 | 5,083 | 19,019 |
| Total revenue | 62,740 | 68,256 | 73,936 | 60,893 | 58,793 | 61,334 | 265,824 |
| EBITDA | 9,409 | 8,436 | 9,877 | 1,211 | -1,501 | -4,242 | 28,930 |
| EBITDA margin (%) | 15.0 | 12.4 | 13.4 | 2.0 | -2.6 | -6.9 | 10.9 |
| EBIT | -2,612 | -3,204 | -1,943 | -10,846 | -12,867 | -23,791 | -18,607 |
| Net profit/loss for the period | -4,728 | -920 | -4,674 | -14,318 | -9,901 | -27,218 | -24,643 |
| Earnings per share, before and after dilution, SEK |
-0.13 | -0.03 | -0.13 | -0.41 | -0.28 | -0.78 | -0.70 |
| Operating cash flow | -12,111 | 18,860 | 8,342 | 16,843 | -19,056 | 10,110 | 31,936 |
| Operating cash flow per share, SEK | -0.35 | 0.54 | 0.24 | 0.48 | -0.54 | 0.29 | 0.91 |
| Net debt | 124,415 | 111,040 | 128,961 | 134,020 | 145,690 | 109,882 | 124,415 |
| Total shares (pcs) | 35,043,885 35,043,885 35,043,885 35,043,885 35,043,885 35,043,885 35,043,885 |
The Board of Directors and the CEO certify that the interim report, to the best of their knowledge, provides a fair overview of the parent company's and the Group's operations, financial position and results and describes the material risks and uncertainties faced by the parent company and the companies included in the Group.
Thomas von Koch Richard Kuntz Chairperson of the Board Board Member
Anna Martling Magdalena Persson Board Member Board Member
Jan Ståhlberg Christine Lind Board Member CEO
This interim report has not been reviewed by the company auditors.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on 24 April 2025, at 07:00 a.m. CET.
This is a translation of the Swedish Interim report. In the event of any discrepancy, the Swedish version applies.
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices.
Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or cobranded with Bactiguard. The company also has a portfolio of wound management products.
Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Read more about Bactiguard bactiguard.com
Follow Bactiguard on LinkedIn
15 July 2025 Interim report second quarter 1 April – 30 June 2025 23 October 2025 Interim report third quarter 1 July – 30 September 2025
For additional information, please contact: Patrick Bach, CFO: +46 8 440 58 80 Nina Nornholm, Head of Communication & Investor Relations: +46 708 550 356
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.